Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Immune Recovery

Long-term persistence of the immune response to antipneumococcal vaccines after Allo-SCT: 10-year follow-up of the EBMT-IDWP01 trial

Bone Marrow Transplantation volume 50, pages 978–983 (2015)Cite this article

Subjects

Abstract

The guidelines for immunization of hematopoietic SCT (HSCT) recipients recommend three doses of antipneumococcal conjugate vaccine (PCV) from 3 to 6 months after transplant, followed by a dose of polysaccharide 23-valent (PPV23) vaccine at 12 months in the case of no GVHD or an additional PCV dose in the case of GVHD. Due to the lack of long-term data in the literature, there is no recommendation for boosts after 12 months. Our goal was to assess the maintenance of the immune response to pneumococcal vaccines in patients vaccinated 10 years ago according to current guidelines. Thirty surviving patients of the IDWP01 (Infectious Diseases Working Party 1) trial were assessed for antibody levels against the seven antigens of the PCV7 and against two of the PPV23-specific antigens. When compared with 24 months after transplant, the immune response did not significantly decrease but with important serotype-specific variability. There was no evidence that an additional dose of PPV23 given to 11/30 patients 2–11 years after transplant was beneficial. In long-term HSCT survivors with no or few GVHD vaccinated against Streptococcus pneumoniae according to the current guidelines, the specific immunity is not fully maintained a decade later. The optimal schedule of antipneumococcal vaccination in HSCT recipients after 12 months remains to be established.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

Similar content being viewed by others

References

  1. Engelhard D, Cordonnier C, Shaw PJ, Parkalli T, Guenther C, Martino R et al. Early and late invasive pneumococcal infection following stem cell transplantation: a European Bone Marrow Transplantation survey. Br J Haematol 2002; 117: 444–450.

    Article  Google Scholar 

  2. Giebink GS, Warkentin PI, Ramsay NK, Kersey JH . Titers of antibody to pneumococci in allogeneic bone marrow transplant recipients before and after vaccination with pneumococcal vaccine. J Infect Dis 1986; 154: 590–596.

    Article  CAS  Google Scholar 

  3. Youssef S, Rodriguez G, Rolston KV, Champlin RE, Raad II, Safdar A . Streptococcus pneumoniae infections in 47 hematopoietic stem cell transplantation recipients: clinical characteristics of infections and vaccine-breakthrough infections, 1989-2005. Medicine (Baltimore) 2007; 86: 69–77.

    Article  Google Scholar 

  4. Ljungman P, Cordonnier C, Einsele H, Englund J, Machado CM, Storek J et al. Vaccination of hematopoietic cell transplant recipients. Bone Marrow Transplant 2009; 44: 521–526.

    Article  CAS  Google Scholar 

  5. Rubin L, Levin M, Ljungman P, Davies E, Avery R, Tomblun M et al. 2013 IDSA Clinical Practice Guideline for Vaccination of the Immunocompromised Host. Clin Infect Dis 2014; 58: 309–318.

    Article  Google Scholar 

  6. Cordonnier C, Labopin M, Chesnel V, Ribaud P, de la Camara R, Martino R et al. Immune response to the 23-valent polysaccharide vaccine after the 7-valent conjugate vaccine in allogeneic stem cell transplant recipients: Results from the EBMT IDWP01 trial. Vaccine 2010; 28: 2730–2734.

    Article  CAS  Google Scholar 

  7. Cordonnier C, Labopin M, Chesnel V, Ribaud P, De La Camara R, Martino R et al. Randomized study of early versus late immunization with pneumococcal conjugate vaccine after allogeneic stem cell transplantation. Clin Infect Dis 2009; 48: 1392–1401.

    Article  CAS  Google Scholar 

  8. Cordonnier C, Labopin M, Jansen KU, Pride M, Chesnel V, Bonnet E et al. Relationship between IgG titers and opsonocytophagocytic activity of anti-pneumococcal antibodies after immunization with the 7-valent conjugate vaccine in allogeneic stem cell transplant. Bone Marrow Transplant 2010; 45: 1423–1426.

    Article  CAS  Google Scholar 

  9. Meisel R, Kuypers L, Dirksen U, Schubert R, Gruhn B, Strauss G et al. Pneumococcal conjugate vaccine provides early protective antibody responses in children after related and unrelated allogeneic hematopoietic stem cell transplantation. Blood 2007; 109: 2322–2326.

    Article  CAS  Google Scholar 

  10. Molrine DC, Antin JH, Guinan EC, Soiffer RJ, MacDonald K, Malley R et al. Donor immunization with pneumococcal conjugate vaccine and early protective antibody responses following allogeneic hematopoietic cell transplantation. Blood 2003; 101: 831–836.

    Article  CAS  Google Scholar 

  11. Esposito S, Tansey S, Thompson A, Razmpour A, Liang J, Jones TR et al. Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine compared to those of a 7-valent pneumococcal conjugate vaccine given as a three-dose series with routine vaccines in healthy infants and toddlers. Clin Vaccine Immunol 2010; 17: 1017–1026.

    Article  CAS  Google Scholar 

  12. Concepcion NF, Frasch CE . Pneumococcal type 22f polysaccharide absorption improves the specificity of a pneumococcal-polysaccharide enzyme-linked immunosorbent assay. Clin Diagn Lab Immunol 2001; 8: 266–272.

    CAS  PubMed  PubMed Central  Google Scholar 

  13. Musher DM, Manoff SB, McFetridge RD, Liss CL, Marchese RD, Raab J et al. Antibody persistence ten years after first and second doses of 23-valent pneumococcal polysaccharide vaccine, and immunogenicity and safety of second and third doses in older adults. Hum Vaccin 2011; 7: 919–928.

    Article  CAS  Google Scholar 

  14. Kumar D, Welsh B, Siegal D, Chen MH, Humar A . Immunogenicity of pneumococcal vaccine in renal transplant recipients—three year follow-up of a randomized trial. Am J Transplant 2007; 7: 633–638.

    Article  CAS  Google Scholar 

  15. Barra A, Cordonnier C, Preziosi MP, Intrator L, Hessel L, Fritzell B et al. Immunogenicity of Haemophilus influenzae type b conjugate vaccine in allogeneic bone marrow recipients. J Infect Dis 1992; 166: 1021–1028.

    Article  CAS  Google Scholar 

  16. Kumar D, Chen MH, Welsh B, Siegal D, Cobos I, Messner HA et al. A randomized, double-blind trial of pneumococcal vaccination in adult allogeneic stem cell transplant donors and recipients. Clin Infect Dis 2007; 45: 1576–1582.

    Article  Google Scholar 

  17. Blum MD, Dagan R, Mendelman PM, Pinsk V, Giordani M, Li S et al. A comparison of multiple regimens of pneumococcal polysaccharide-meningococcal outer membrane protein complex conjugate vaccine and pneumococcal polysaccharide vaccine in toddlers. Vaccine 2000; 18: 2359–2367.

    Article  CAS  Google Scholar 

  18. de Roux A, Schmole-Thoma B, Siber GR, Hackell JG, Kuhnke A, Ahlers N et al. Comparison of pneumococcal conjugate polysaccharide and free polysaccharide vaccines in elderly adults: conjugate vaccine elicits improved antibacterial immune responses and immunological memory. Clin Infect Dis 2008; 46: 1015–1023.

    Article  Google Scholar 

  19. O'Brien KL, Hochman M, Goldblatt D . Combined schedules of pneumococcal conjugate and polysaccharide vaccines: is hyporesponsiveness an issue? Lancet Infect Dis 2007; 7: 597–606.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

We are grateful to Luca Mollo, MD (Medical Director Vaccines, Pfizer, France) and Veronique Schindler (IIR Manager, Pfizer France), Linda Xu (Data management and logistics, Vaccines R and D, Pfizer Laboratories, Pearl River, US) and Adriana Cahill (WW Research &Development, Vaccines R and D, Pfizer Laboratories, Pearl River, US) for their help in the organization of the study and the laboratory assessments. We also thank the staff of the Plateforme de Ressources Biologiques of Henri Mondor University Hospital, especially Dr Bijan Ghaleh and Dr Caroline Barau, and Dr Oumedaly Reman, Caen University Hospital. This work was supported by Pfizer France.

Author contributions

CC and PL: study concept and design, funding, acquisition of data, analysis and interpretation of data and drafting the manuscript. ML: statistical analysis and drafting the manuscript. PR: study concept, acquisition of data and analysis and interpretation of data. CR, LC and CCh: data collection and analysis and interpretation of data. SC: critical revision of the manuscript.

Author information

Authors and Affiliations

  1. Hematology Department, Henri Mondor Teaching Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP) and Paris-Est Créteil University, Créteil, France

    C Cordonnier, C Robin & L Cabanne

  2. EBMT Data and Study Office, Saint-Antoine Teaching Hospital, AP-HP,

    M Labopin

  3. and UPMC Paris 6 University, INSERM UMR-S 893 Group 14, Paris Cedex 12, France

    M Labopin

  4. Service d'Hématologie-Greffe de Moelle, APHP Hôpital Saint-Louis,

    P Ribaud & C Chadelat

  5. and Université Paris Diderot, Sorbonne Paris-Cité, Paris, France

    P Ribaud & C Chadelat

  6. Policlinico G.B. Rossi, Paediatric Haematology Oncology, Verona, Italy

    S Cesaro

  7. Department of Hematology, Karolinska University Hospital, Karolinska Institutet,

    P Ljungman

  8. Division of Hematology, Department of Medicine Huddinge, Karolinska Institutet, Stockholm, Sweden

    P Ljungman

Authors
  1. C Cordonnier
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M Labopin
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. C Robin
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. P Ribaud
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. L Cabanne
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. C Chadelat
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. S Cesaro
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. P Ljungman
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to C Cordonnier or P Ljungman.

Ethics declarations

Competing interests

Dr Cordonnier served on Pfizer advisory boards and speaker bureau and received research funding for her department. Dr Ribaud served on Pfizer advisory boards and speaker bureau. Dr Ljungman has been an investigator on a subsequent Pfizer sponsored study and participated on behalf of his department in a Pfizer advisory board. The remaining authors declare no potential conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Cordonnier, C., Labopin, M., Robin, C. et al. Long-term persistence of the immune response to antipneumococcal vaccines after Allo-SCT: 10-year follow-up of the EBMT-IDWP01 trial. Bone Marrow Transplant 50, 978–983 (2015). https://doi.org/10.1038/bmt.2015.42

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2015.42

This article is cited by

Search

Advanced search

Quick links